Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 11


Genistein increases estrogen receptor beta expression in prostate cancer via reducing its promoter methylation.

Mahmoud AM, Al-Alem U, Ali MM, Bosland MC.

J Steroid Biochem Mol Biol. 2015 Aug;152:62-75. doi: 10.1016/j.jsbmb.2015.04.018. Epub 2015 Apr 27.


Genome-wide microarray expression and genomic alterations by array-CGH analysis in neuroblastoma stem-like cells.

Ordóñez R, Gallo-Oller G, Martínez-Soto S, Legarra S, Pata-Merci N, Guegan J, Danglot G, Bernheim A, Meléndez B, Rey JA, Castresana JS.

PLoS One. 2014 Nov 13;9(11):e113105. doi: 10.1371/journal.pone.0113105. eCollection 2014.


Subtype-specific overexpression of the Rac-GEF P-REX1 in breast cancer is associated with promoter hypomethylation.

Barrio-Real L, Benedetti LG, Engel N, Tu Y, Cho S, Sukumar S, Kazanietz MG.

Breast Cancer Res. 2014 Sep 24;16(5):441. doi: 10.1186/s13058-014-0441-7.


Low-dose decitabine-based chemoimmunotherapy for patients with refractory advanced solid tumors: a phase I/II report.

Fan H, Lu X, Wang X, Liu Y, Guo B, Zhang Y, Zhang W, Nie J, Feng K, Chen M, Zhang Y, Wang Y, Shi F, Fu X, Zhu H, Han W.

J Immunol Res. 2014;2014:371087. doi: 10.1155/2014/371087. Epub 2014 May 21.


Pemetrexed and gemcitabine as combination therapy for the treatment of Group3 medulloblastoma.

Morfouace M, Shelat A, Jacus M, Freeman BB 3rd, Turner D, Robinson S, Zindy F, Wang YD, Finkelstein D, Ayrault O, Bihannic L, Puget S, Li XN, Olson JM, Robinson GW, Guy RK, Stewart CF, Gajjar A, Roussel MF.

Cancer Cell. 2014 Apr 14;25(4):516-29. doi: 10.1016/j.ccr.2014.02.009. Epub 2014 Mar 27.


Therapeutic targets for neuroblastomas.

Brodeur GM, Iyer R, Croucher JL, Zhuang T, Higashi M, Kolla V.

Expert Opin Ther Targets. 2014 Mar;18(3):277-92. doi: 10.1517/14728222.2014.867946. Epub 2014 Jan 6. Review.


Epigenetic changes in pediatric solid tumors: promising new targets.

Lawlor ER, Thiele CJ.

Clin Cancer Res. 2012 May 15;18(10):2768-79. doi: 10.1158/1078-0432.CCR-11-1921. Review.


Epigenetic reprogramming reverses the relapse-specific gene expression signature and restores chemosensitivity in childhood B-lymphoblastic leukemia.

Bhatla T, Wang J, Morrison DJ, Raetz EA, Burke MJ, Brown P, Carroll WL.

Blood. 2012 May 31;119(22):5201-10. doi: 10.1182/blood-2012-01-401687. Epub 2012 Apr 11.


Treatment with the cancer drugs decitabine and doxorubicin induces human skin keratinocytes to express Oct4 and the OCT4 regulator mir-145.

Chinnathambi S, Wiechert S, Tomanek-Chalkley A, Winter MC, Bickenbach JR.

J Dermatol. 2012 Jul;39(7):617-24. doi: 10.1111/j.1346-8138.2012.01553.x. Epub 2012 Apr 9.



Davidoff AM.

Semin Pediatr Surg. 2012 Feb;21(1):2-14. doi: 10.1053/j.sempedsurg.2011.10.009. Review.


Improving T-cell therapy for relapsed EBV-negative Hodgkin lymphoma by targeting upregulated MAGE-A4.

Cruz CR, Gerdemann U, Leen AM, Shafer JA, Ku S, Tzou B, Horton TM, Sheehan A, Copeland A, Younes A, Rooney CM, Heslop HE, Bollard CM.

Clin Cancer Res. 2011 Nov 15;17(22):7058-66. doi: 10.1158/1078-0432.CCR-11-1873. Epub 2011 Sep 9. Erratum in: Clin Cancer Res. 2012 Feb 1;18(3):913. Dosage error in article text.

Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk